Posted in | News | Medical Robotics

Detecting Pancreatic Cancer with Machine Learning and miRNA

In a recent study published in the journal BJC | British Journal of Cancer, researchers explored a novel approach for detecting pancreatic cancer, a disease known for its aggressive nature and poor prognosis.

The researchers combined serum microribonucleic acid or microRNA (miRNA) sequencing with machine learning (ML) techniques to develop accurate diagnostic models for identifying the disease in its often asymptomatic early stages.

Detecting Pancreatic Cancer with ML and miRNA
a) All the 425 serum samples, including 213 pancreatic cancer patients from 14 hospitals and 212 healthy controls without cancer from three clinics, were randomly divided into the training and validation cohorts. Image Credit: https://www.nature.com/articles/s41416-024-02794-5

Background

Pancreatic cancer is among the most lethal cancers, with a five-year survival rate of only 12%. It is the fourth leading cause of cancer-related deaths worldwide, and its prevalence is expected to rise, potentially becoming the second deadliest cancer by 2030.

Early detection is crucial for improving patient outcomes but remains challenging due to a lack of specific symptoms and reliable biomarkers. Current diagnostic methods, such as imaging and tumor marker analysis like CA19-9, have limitations in sensitivity and specificity, especially for early-stage detection.

miRNAs are small non-coding ribonucleic acid (RNA) molecules that regulate gene expression. They are found in stable forms in bodily fluids, making them potential indicators for various diseases, including cancer.

The advancement in high-throughput sequencing has enabled comprehensive analysis of miRNA expression profiles, providing a powerful tool for identifying potential biomarkers for disease diagnosis and prognosis.

About the Research

In this paper, the authors aimed to develop an innovative technique for early detection of pancreatic cancer by analyzing comprehensive serum miRNA expression profiles using automated ML. Serum samples were collected from 213 pancreatic cancer patients and 212 healthy controls, representing a diverse cohort from 14 hospitals and three clinics.

These samples underwent miRNA sequencing on next-generation sequencing (NGS) platforms, including the NextSeq 550 and Ion GeneStudio S5 systems, to generate a detailed dataset of miRNA expression profiles. Various statistical and ML techniques were then applied to these data to build and validate diagnostic models.

To identify potential biomarkers, the researchers used DataRobot, an automated ML (AutoML) platform, to develop diagnostic models based on the expression profiles of 100 miRNAs and their connection with CA19-9. DataRobot is a powerful tool that automatically generates and evaluates various ML models.

The platform analyzed the miRNA expression data using 64 algorithms, including elastic net and light gradient boosting. Model performance was assessed using a 5-fold cross-validation approach, which repeatedly split the data into training and testing sets to ensure model generalizability.

The study focused on identifying a set of miRNAs that could effectively discriminate between patients with pancreatic cancer and healthy controls. The authors also investigated the potential of combining these miRNAs with the established tumor marker CA19-9 to enhance diagnostic accuracy further.

Research Findings

The outcomes showed that the presented technique accurately detected pancreatic cancer with high sensitivity and specificity. The authors identified 100 highly expressed miRNAs significantly associated with pancreatic cancer.

Combining these miRNAs with CA19-9 achieved an impressive area under the curve (AUC) of 0.99, with a sensitivity of 90% and specificity of 98%, demonstrating the model's strong ability to differentiate between pancreatic cancer patients and healthy controls.

The study also found that the ML model could effectively detect pancreatic cancer in early stages (stage 0-I) with high accuracy. This result is significant since early detection improves treatment outcomes and survival rates.

The model's performance was validated using an independent cohort of 21 asymptomatic patients with pancreatic cancer, further confirming its accuracy and potential for early diagnosis. The models outperformed conventional serum markers like CA19-9, CEA, and DUPAN-2, especially in detecting early-stage disease.

Applications

This research has significant implications for the early detection and treatment of pancreatic cancer. Comprehensive serum miRNA sequencing combined with AutoML provides a non-invasive and highly accurate method for detecting pancreatic cancer, potentially enabling earlier diagnosis and more effective treatment strategies.

This approach could also be applied to other cancer types, allowing for the early detection and treatment of a broader range of malignancies. Additionally, using automated ML platforms like DataRobot can accelerate the discovery of new biomarkers and the development of precise diagnostic tools.

Conclusion

In summary, the proposed approach proved highly effective, accurate, and robust for detecting cancer, particularly pancreatic cancer, at an early stage. It has the potential to transform cancer diagnosis and treatment by serving as a non-invasive screening tool for high-risk groups, such as individuals with a family history of pancreatic cancer or certain genetic syndromes.

Early detection of pancreatic cancer could improve patient health through timely intervention and treatment. Future research should focus on validating these models in larger, prospective studies and assessing their applicability in clinical settings.

Journal Reference

Kawai, M., Fukuda, A., Otomo, R. et al. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated Machine Learning. Br J Cancer (2024). DOI: 10.1038/s41416-024-02794-5, https://www.nature.com/articles/s41416-024-02794-5

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Muhammad Osama

Written by

Muhammad Osama

Muhammad Osama is a full-time data analytics consultant and freelance technical writer based in Delhi, India. He specializes in transforming complex technical concepts into accessible content. He has a Bachelor of Technology in Mechanical Engineering with specialization in AI & Robotics from Galgotias University, India, and he has extensive experience in technical content writing, data science and analytics, and artificial intelligence.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Osama, Muhammad. (2024, September 03). Detecting Pancreatic Cancer with Machine Learning and miRNA. AZoRobotics. Retrieved on October 10, 2024 from https://www.azorobotics.com/News.aspx?newsID=15215.

  • MLA

    Osama, Muhammad. "Detecting Pancreatic Cancer with Machine Learning and miRNA". AZoRobotics. 10 October 2024. <https://www.azorobotics.com/News.aspx?newsID=15215>.

  • Chicago

    Osama, Muhammad. "Detecting Pancreatic Cancer with Machine Learning and miRNA". AZoRobotics. https://www.azorobotics.com/News.aspx?newsID=15215. (accessed October 10, 2024).

  • Harvard

    Osama, Muhammad. 2024. Detecting Pancreatic Cancer with Machine Learning and miRNA. AZoRobotics, viewed 10 October 2024, https://www.azorobotics.com/News.aspx?newsID=15215.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.